Investor Presentation

Limited July 30, 2026 Ref:- GHL/2026-27/EXCH/36 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Investor Presentation Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the first quarter ended June 30, 2026 Results. Kindly take the above on record. Thanking you, Yours faithfully For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q1 FY2027 30th July, 2026 Disclaimer This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company. • These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes. Contents 01 Q1 FY2027 Performance Update 02 Project Update and Capex Plan 03 Medanta’s Journey, Purpose and Model of Healthcare 04 Annexures 01 Q1 FY2027 Performance Update Q1 FY2027 performance summary Revenue Growth of 26% y-o-y and EBITDA ex Noida growth of 24% y-o-y; Growth led by patient volumes Total Income1 EBITDA3 and Margins Profit after Tax and Margins EBITDA2 ex Noida Reported EBITDA INR 1,573 million INR 3,201 million INR 3,153 million INR 13,262 million Margin: 11.9% Margin: 25.8% Margin: 23.8% Q1 FY26 Q1 FY26 Q1 FY26 Q1 FY26 2,584 million 2,553 million 1,590 million 23.9% 23.5% -1.1% 10,513 million 26.2% Margin: 24.6% Margin: 24.3% Margin: 15.1% Occupied Bed Days ARPOB* | ARPP* (INR) ALOS (days) Patient Footfalls 60,214 1,100,928 173,064 70,244 2-01,891 2.87 In-patients Out-patients** Q1 FY26 Q1 FY26 5.5% nm 27.7% 34.5% 142,898 21.1% 3.03 -5.2% Q1 FY26 Q1 FY26 Q1 FY26 Q1 FY26 66,584 201,795 47,150 818,815 1. Noida generated Total Income of INR 855 million 2. Noida EBITDA loss narrowed to INR 49 million in Q1 FY27 from INR 236 million in Q4 FY26. Q1 FY26 EBITDA loss stood at INR 30 million 3. EBITDA represents EBITDA before ESOP expenses *ARPOB is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Occupied bed days; ARPP is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by Inpatient Volumes ** Outpatients volume reflects OPD encounters Q1 FY2027 performance summary Revenue growth of 26% y-o-y, primarily led by increase in patient volumes and realization Highest ever quarterly total income of INR 13,262 million; growth of 26.2% y-o-y • EBITDA1 (ex-Noida) grew 23.9 % y-o-y to INR 3,201 with improved margins of 25.8% in Q1 FY27. EBITDA including Noida was INR 3,153 million, growth of ~ 23.5% y-o-y and margins of 23.8% ~ Noida hospital generated Total Income of INR 855 million and EBITDA loss of INR 49 million in Q1 FY27, compared to total income of INR 525 million and IE BITDA loss of INR 236 million reported in Q4 FY26 Profit After Tax was INR 1,573 million, compared to INR 1,590 million in Q1FY6. PAT margins were at 11.9% compared to 15.1% in Q1 FY26. To highlight, ~ Q1FY26 had a non-recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL During the quarter, total 72 new beds were added across the network; 21 beds were added at Lucknow and 51 beds in Noida Volume growth continues to remain robust, In-patient count increased by 27.7% while Out-patient count increased by 34.5% y-o-y Occupied bed days increased by 21.1% y-o-y, representing an occupancy of ~63% on increased bed capacity while excluding Noida, occupancy stood at 66% ARPOB stood at INR 70,224, up by 5.5% y-o-y, driven by improvement in ALOS (from 3.03 days in Q1FY26 to 2.87 days in Q1FY27) and change in case mix ~ ARPP for the quarter was INR 201,891, compared to INR 201,795 in same quarter last year. • During the quarter, International Patients Revenue increased by 23.0% y-o-y to INR 782 million ~ OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 50.9% y-o-y to INR 609 million in Q1 FY27 1. EBITDA represents EBITDA before ESOP expenses 6 Q1 FY2027 clinical achievements Continuing the legacy of clinical excellence • A 45-year-old critically ill lung adenocarcinoma patient with complete left lung collapse and ventilator-dependent respiratory failure was I successfully treated at Medanta Gurugram using VV-ECMO-supported therapeutic bronchoscopy, tumour debulking (electrocautery and cryotherapy) and Y-stent placement, restoring airway patency and re-expanding the collapsed lung IM edanta Gurugram successfully treated a rare case of DYT1 dystonia in a 12-year-old patient using Deep Brain Stimulation (DBS), restoring the patient's ability to walk A 61-year-old woman with a rare and life-threatening paraesophageal hernia with gastric volvulus underwent robotic-assisted paraesophageal hernia repair with gastropexy at Medanta Noida and was discharged within three days Medanta Lucknow crossed the milestone of 1,000 joint replacement surgeries using advanced robotic technology within one year of launch of robotic orthopaedic and joint replacement program, reflecting the rapid scale-up of the robotic program Medanta Lucknow became the first private healthcare institution in Uttar Pradesh to successfully performed a Whole Lung Lavage for Ia patient with Pulmonary Alveolar Proteinosis (PAP) Doctors at Medanta Patna successfully performed the unit's first Transarterial Chemoembolization procedure for a patient with hepatocellular carcinoma and decompensated chronic liver disease (Child-Pugh B8), marking a significant milestone in advanced liver cancer care. A critically ill 10-month-old infant suffering from hepatoblastoma and acute kidney injury was successfully treated at Medanta Patna Iu sing Continuous Renal Replacement Therapy (CRRT). The case is likely the first in Bihar where a specialized bilirubin adsorption system was connected in series with a plasma filter, helping save the child's life Q1 FY2027 Business Update Strengthening the core and building strong pipeline for growth Capacity Expansion New Medical Equipment Deployed in Q1 FY27  Noida: 51 beds added on 9th Floor A-Wing  Lucknow: 21 beds added on the 9th floor of Tower A  Ranchi: Launched Surgical Oncology services  Indore Cancer Unit: Addition of an 80-bed cancer hospital, announced in April 2026, to be operationalized in Q2/Q3 FY27. Equipment Procurement and on-boarding of clinicians on track. MISSO Ortho Robotic Stealth Station S8 -Surgical J&J VELYS Orthopaedic Surgical System -Gurugram Navigation System Lucknow Robot –Lucknow & Patna Attract Best Talent Continuity of Care  70+ Doctors o [Showing first 8,000 characters — download PDF for full document]